Azitra, Inc. Files S-1/A Amendment
Ticker: AZTR · Form: S-1/A · Filed: Jul 19, 2024 · CIK: 1701478
Sentiment: neutral
Topics: sec-filing, s-1/a, pharmaceuticals
TL;DR
Azitra S-1/A filed. Public offering incoming.
AI Summary
Azitra, Inc. filed an S-1/A amendment on July 19, 2024, to its registration statement. The company, incorporated in Delaware with its principal executive offices at 21 Business Park Drive, Branford, CT 06405, is in the Pharmaceutical Preparations industry (SIC code 2834). This filing is related to SEC file number 333-280806.
Why It Matters
This S-1/A filing indicates Azitra, Inc. is moving forward with its public offering process, which could provide significant capital for its pharmaceutical development efforts.
Risk Assessment
Risk Level: medium — As a company in the pharmaceutical preparations sector undergoing a public offering, Azitra faces inherent risks related to regulatory approval, clinical trials, and market competition.
Key Numbers
- 333-280806 — SEC File Number (Identifies the registration statement with the SEC.)
- 2834 — SIC Code (Classifies Azitra, Inc. in the Pharmaceutical Preparations industry.)
Key Players & Entities
- Azitra, Inc. (company) — Registrant
- 21 Business Park Drive, Branford, CT 06405 (address) — Principal Executive Offices
- Francisco D. Salva (person) — Agent for Service
- Daniel K. Donahue, Esq. (person) — Counsel
- Greenberg Traurig, LLP (company) — Legal Counsel
- 333-280806 (registration_number) — SEC File Number
- 2834 (sic_code) — Pharmaceutical Preparations Industry
FAQ
What is the purpose of this S-1/A filing?
This is an amendment to the Form S-1 registration statement filed by Azitra, Inc. with the SEC.
When was this amendment filed?
The amendment was filed on July 19, 2024.
What is Azitra, Inc.'s principal executive office address?
Azitra, Inc.'s principal executive offices are located at 21 Business Park Drive, Suite 6, Branford, CT 06405.
Who is listed as the agent for service for Azitra, Inc.?
Francisco D. Salva is listed as the agent for service, with the same address as the principal executive offices.
What is the SEC file number associated with this registration?
The SEC file number is 333-280806.
Filing Stats: 4,590 words · 18 min read · ~15 pages · Grade level 14 · Accepted 2024-07-19 17:27:47
Key Financial Figures
- $0.0001 — ne share of our common stock, par value $0.0001 per share (the “common stock&rdqu
- $3 — public offering price for each Unit is $3.21, which was the last reported sale pr
- $3.21 — of 3.21 (assuming an offering price of $3.21 per Unit) per share of common stock, an
- $0 — d to the public in this offering, minus $0.0001, and the exercise price of each Pr
- $3,2099 — ncluding one Pre-Funded Warrant will be $3,2099. (2) We have agreed to pay the placem
- $100,000 — and other out-of-pocket expenses, up to $100,000. In addition, we have agreed to issue t
- $4.0125 — nded Warrants), at an exercise price of $4.0125 per share, which represents 125% of the
- $8 million — ains. In December 2020, Bayer purchased $8 million of our Series B preferred stock, which
Filing Documents
- forms-1a.htm (S-1/A) — 566KB
- ex23-2.htm (EX-23.2) — 4KB
- ex23-2_001.jpg (GRAPHIC) — 11KB
- ex23-2_002.jpg (GRAPHIC) — 7KB
- ex23-2_003.jpg (GRAPHIC) — 17KB
- logo_001.jpg (GRAPHIC) — 12KB
- forms-1_001.jpg (GRAPHIC) — 27KB
- 0001493152-24-028577.txt ( ) — 673KB
RISK FACTORS
RISK FACTORS 8 SUMMARY FINANCIAL DATA 9 RISK FACTORS 10 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 14 TRADEMARKS, SERVICE MARKS AND TRADE NAMES 15 USE OF PROCEEDS 16 DIVIDEND POLICY 17 CAPITALIZATION 18 DESCRIPTION OF SECURITIES 19 SHARES ELIGIBLE FOR FUTURE SALE 26 PLAN OF DISTRIBUTION 27 LEGAL MATTERS 31 EXPERTS 31 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 31 WHERE YOU CAN FIND MORE INFORMATION 31 You should rely only on the information contained in this prospectus or incorporated by reference. We have not authorized any other person to provide you with information different from or in addition to that contained in this prospectus, and we take no responsibility for any other information others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. Except as otherwise stated, you should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus and that the information in any report incorporated by reference is accurate only as of the date of such report. Our business, financial condition, results of operations and prospects may have changed since such dates. No action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction. As used in this prospectus, unless the context indicates or otherwise requires, “the Company,” “our Company,” “we,” “us,” and &ld